NIAID Adjuvant Development Contract: Development of TRAC-478: A Synthetic Dual TLR Adjuvant Combination System; 9/30/2020 – 9/29/2023
NIAID Adjuvant Development Contract: Boston Children’s Hospital; 9/30/2020 – 9/29/2023
SBIR Phase I Adjuvant Discovery Contract: New small molecule TLR4 agonists for the treatment of Allergic Rhinitis; 8/2018 – 8/2020
R01 Grant Subaward: Immunization against filamentous bacteriophages to prevent bacterial infection; 6/8/2018 – 2/31/2023
SBIR Phase II – Upper Respiratory Tract Infections; 9/1/2019 – 08/31/2121
3 Adjuvant Discovery Sub-Contracts (UM/Duke University, Oregon Health Sciences University, Boston Children’s Hospital); 9/30/2019 – 9/29/2024
Dept. of Defense MRMC Grant for Berkeleylactone development (joint with UM); 2020-2022
Opioid Vaccine Contracts: University of Montana & Boston Children’s Hospital (Subawards to Inimmune); June 2020-May 2022
SBIR Phase II Contract for multi-component adjuvant formulations; September 2020-August 2025
TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING
Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Professional doctor or nurse giving flu or COVID-19 injection to patient. Woman in medical face mask getting antiviral vaccine at hospital or health center during vaccination and immunization campaign.